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A Ab bs st tr ra ac ct t
Cowden syndrome (multiple hamartoma syndrome, MIM 158350) is an early onset syndrome characterized by
multiple hamartomas in the skin, mucous membranes, breast, thyroid and endometrium. Patients with Cowden
syndrome have increased risk of breast cancer, thyroid cancer and endometrial cancer. In 1997 germline
mutations in PTEN were demonstrated to cause Cowden syndrome. We report the results of diagnostic and
predictive testing in all families with Cowden syndrome or suspected Cowden syndrome registered at the
Norwegian cancer family clinics. PTEN mutations were found in all six families meeting the clinical criteria for
Cowden syndrome, in none of the two families assumed to have Cowden syndrome but not fulfilling the criteria,
and in none of the eight families selected in our computerized medical files to have a combination of breast
and thyroid cancers. Age-related penetrances for the various neoplasms are given. All families but one were
small and de novo mutations were found.
I In nt tr ro od du uc ct ti io on n
In 1963 Lloyd and Dennis described a patient
named Rachel Cowden who died of bilateral breast
cancer in her thirties [1]. Cowden syndrome is now
recognized as an autosomal dominant syndrome
characterized by multiple hamartomas originating from
all three germ-cell layers. Mucocutaneous lesions
including trichilemmomas are seen in 90-100% of
patients [2]. There is increased risk of early breast
cancer from 14 years of age, and lifetime risk is
estimated to 25-50% [3-5]. Goitre and thyroid
adenomas are frequently seen and the estimated
prevalence of thyroid cancer is 3-7% [3, 6, 7]. We have
previously reported endometrial cancer in one
Norwegian family with Cowden syndrome [8]. 
In 1995 the International Cowden Syndrome
Consortium was formed and a set of clinical diagnostic
criteria were suggested; see Table 1 [2, 9, 10]. In 1997
the susceptibility gene for Cowden syndrome was
identified on chromosome 10q23.3 and was found to
be PTEN [11, 12]. Germline mutations are found
throughout the PTEN gene, the majority in exons 5, 7
and 8 [2, 13]. The frequency of germline PTEN
mutations, including mutations in the promoter region,
in Cowden syndrome have been reported to approach
85-90% [14]. Genotype/phenotype correlations have
been suggested, but have not been confirmed [15-17]. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(4) 178
Cecilie F Rustad, Merete Bjørnslett, Ketil R Heimdal, Lovise Mºhle, Jaran Apold, Pål Møller
T Ta ab bl le e   1 1. .   International Cowden Syndrome Consortium operational criteria (version 2000) as given by Charis Eng [2]
P Pa at th ho og gn no om mo on ni ic c   c cr ri it te er ri ia a
Trichilemmomas, facial
Acral keratoses
Papillomatous papules
Mucosal lesions
M Ma aj jo or r   c cr ri it te er ri ia a
Breast carcinoma
Thyroid carcinoma (non-medullary), especially follicular thyroid carcinoma
Macrocephaly (megalencephaly) (say >97 percentile)
Lhermitte-Duclos disease
Endometrial carcinoma
M Mi in no or r   c cr ri it te er ri ia a
Other thyroid lesions (e.g. adenoma or multinodular goitre)
Mental retardation
Gastrointestinal hamartomas
Fibrocystic disease of the breast
Lipomas
Fibromas
Gastrointestinal tumours (e.g. renal cell carcinoma, uterine fibroids) or malformation
O Op pe er ra at ti io on na al l   d di ia ag gn no os si is s   i in n   a an n   i in nd di iv vi id du ua al l
1. Mucocutaneous lesions alone if
a. there are six or more facial papules, of which three or more must be trichilemmoma, or
b. cutaneous facial papules and oral mucosal papillomatosis, or
c. oral mucosal papillomatosis and acral keratoses, or
d. palmo-plantar keratoses, 6 or more
2. Two major criteria but one must include macrocephaly or LDD
3. One major and three minor criteria
4. Four minor criteria
O Op pe er ra at ti io on na al l   d di ia ag gn no os si is s   i in n   a a   f fa am mi il ly y   w wh he er re e   o on ne e   i in nd di iv vi id du ua al l   i is s   d di ia ag gn no os st ti ic c   f fo or r   C Co ow wd de en n   s sy yn nd dr ro om me e
1. The pathognomonic criterion/criteria
2. Any major criterion with or without minor criteria
3. Two minor criteria
Nelen has estimated the incidence to be between
1 per 200,000 and 1 per 250,000 in the Dutch
population [16]. 
As for all inherited cancer syndromes, the
penetrance of the underlying genetic defects and the
full clinical spectrum of their expressions have been
difficult to assess without access to genetic testing. 
Fifty to sixty percent of patients with Bannayan-Riley-
Ruvalcaba syndrome (BRRS, MIM 153480) have been
shown to have germline mutations in the PTEN gene
[14, 18]. An association between germline PTEN
mutations and Proteus syndrome (MIM 176920) has
been disputed [19-22].
Our aim was to validate strategies to identify families
with PTEN mutations and to estimate prevalences and
penetrances of PTEN mutations.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s
The computerized medical files at the Section for
Inherited Cancer, Rikshospitalet-Radiumhospitalet
Medical Centre, include more than 40,000 patients
belonging to more than 3,000 families. These files were
analyzed and all families with a diagnosis of Cowden
syndrome, all families suspected to have Cowden
syndrome, and all families with a combination of breast
and thyroid cancers were identified. All of the five other
Norwegian genetic centres contributed their families
with Cowden stigmata. The four families previously
reported to harbour PTEN mutations were included.
We had no families with suspected Bannayan-Riley-
Ruvalcaba syndrome, Proteus syndrome or Proteus-like
syndrome. Our two patients with Lhermitte-Duclos
disease were also classified as having Cowden
syndrome and included above.
All families were extended and offered genetic testing
according to our genetic health care standards [23].
Because all activity was provided as health service, all
information was kept in the medical files and no research
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Norwegian legislation. All diagnoses were confirmed in
the medical files after written informed consent from
each patient if alive or from their relatives if dead. All
family members were offered genetic counselling. All
genetic testing was subjected to written informed consent. 
We sequenced all nine exons, their flanking areas
and 1500 basepairs upstream of ATG (the promoter
region) in the PTEN gene in all patients examined. 
Kaplan-Meier survival estimates were calculated using
the computer program Systat 10
©. The data were stored
in Oracle
©, pedigrees were displayed in Cyrillic
© and the
application to run the database as an electronic patient
file system was programmed in dB+
©. 
R Re es su ul lt ts s
We identified six families (family A, B, C, D, E and
F) which fulfilled the International Cowden Syndrome
Consortium Criteria; for details see Table 2. Four of
them had been identified prior to the present study 
(B, C, D, F) [8]. Two families (G and H) had been
clinically assumed to have Cowden syndrome earlier on,
but did not fulfil the diagnostic criteria. Eight families had
a combination of breast cancer and thyroid cancer.
Mutations in the coding sequence of PTEN were
identified in all living affected members of the six families
fulfilling the International Cowden Syndrome Consortium
Criteria. All together 56 persons were subjected to
genetic testing, out of whom 19 were identified as
mutation carriers. None of the 37 healthy relatives in
these families had mutations. In the two families clinically
assumed to have Cowden syndrome, but not fulfilling
the clinical criteria, no PTEN mutation was identified;
for details see Table 3. In the eight families selected by
a combination of breast and thyroid cancer no PTEN
mutation was identified. Different cancer types were seen
in these families; for details see Table 3. 
Of the tested families, five families had a frameshift
or nonsense mutation and one family had two missense
mutations located in exon 9 located on the same
chromosome. The detected mutations were located in
exon 1 (c.50delAA and c.68T>A), exon 5 (c.328C>T),
exon 6 (c.565A>T), exon 8 (c.1008C>G) and exon 
9 (c.1028T>A and c.1039T>C) (reference sequence:
NM_000314.1). No mutations were found in regulatory
regions.
Except for one family (F), the mutation carrying
families were small. One family had a demonstrated
de novo mutation (D) and two families most likely had
de novo mutations (C and E). We did not observe
skipped generations. 
The mothers of three of our probands had had
breast cancer at age 45 (bilateral breast cancer), 
46 and 56 (bilateral breast cancer) years old. Since
they all were deceased and our attempts to perform
mutation analysis from paraffin embedded tissue from
these patients were unsuccessful, they were considered
to be mutation carriers by state. 
All mutation carriers were examined and all had
clinical signs. The youngest mutation carrier was born
with a demonstrated clinical sign (macrocephaly, 
D-18). Most patients had more than one clinical sign;
for details see Table 2. Twelve (63.2%) patients had
goitre and/or adenoma of the thyroid gland, ten
(52.6%) patients had polyps of the gastrointestinal tract,
seven (36.8%) patients had benign tumours of the
breast, seven (36.8%) patients had endometrial polyps
and/or hyperplasia; for details see Table 3. Fig. 1
shows age-related distribution of first clinical sign, as
estimated by the Kaplan-Meier algorithm.
One patient (A-1) had multiple small colonic polyps
interpreted as not having any dysplasia at age 33. Two
years later she still had multiple small polyps less than
5 millimetres in diameter, now histologically described
as lymphoid infiltrations and interpreted as an
inflammatory condition. Mutation analysis of the APC
gene showed APC 7542 G>A, G2502S and APC
1496 C>T, Y486Y, interpreted as normal variation.
MYH testing was normal. 
Macrocephaly is defined as a head circumference
above the 97
th percentile [2]. We used centile charts
for Norwegian boys and girls aged 0-17 and for all
patients above 17 years of age we used the centile for
age 17. All our patients that were alive were clinically
assessed to have macrocephaly. Macrocephaly was
confirmed by exact measurement in 15 patients and
judged to be clinically present in the remaining four. 
Cancer appeared from age 11. The oldest mutation
carrier without diagnosed neoplasia was 49 years old.
She had, however, been hysterectomized at age 45.
Five (26.3%) patients had breast cancer, age range
from 24 to 45 years. Three (15.8%) patients had thyroid
cancer, age range 11-45 years. Three (15.8%) patients
had tumours of the brain (two had a gangliocytoma at
age 24 and 51 and one had a tumour of the pineal
gland at age 42). Two (10.5%) patients had endometrial
cancer at 31 and 47 years of age. One (5.3%) patient
had kidney cancer at 52 years of age. For details, see
Table 3. Results of Kaplan-Meier analysis for age of
onset of cancer are given in Fig. 2.
D Di is sc cu us ss si io on n
Cowden syndrome is rarely found in families
attending our cancer genetics clinic. In the national
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Germline PTEN mutations are rare and highly penetrant
survey presented here, PTEN mutations were found
in all families fully meeting the Cowden syndrome
criteria, but in no Cowden syndrome-like families not
meeting the criteria. Penetrance of PTEN mutations
was high and expressions were Cowden syndrome
stigmata in early infancy or childhood and cancer in
adolescence or early adulthood [24, 25]. In addition,
the families were small with demonstrated de novo
mutations, indicating low fitness before modern
treatment and low population burden of mutation
carriers. 
Ten years ago we reported the well defined Cowden
syndrome families we knew at the time at Rikshospitalet-
Radiumhospitalet Medical Centre [8]. The national survey
presented here revealed just two additional families, both
fulfilling the clinical criteria for Cowden syndrome.
Obviously, the numbers are too small to arrive at
conclusions with respect to clinical manifestations in the
mutation carriers. On the other hand, we had a large
sample of cancer families initially not ascertained through
Cowden criteria – the families may be representative for
families selected this way. On the other hand, we did not
T Ta ab bl le e   3 3. . Number of patients with benign neoplasms and different cancer types, and the age range
P PT TE EN N   m mu ut ta at ti io on n   p po os si it ti iv ve e   f fa am mi il li ie es s    A As ss su um me ed d   C Co ow wd de en n   s sy yn nd dr ro om me e    B Br re ea as st t- -   a an nd d   t th hy yr ro oi id d- -c ca an nc ce er r   
f fu ul lf fi il ll li in ng g   t th he e   C Co ow wd de en n   s sy yn nd dr ro om me e    f fa am mi il li ie es s   b bu ut t   n no ot t   f fu ul lf fi il ll li in ng g    k ki in nd dr re ed ds s, ,   n no o   P PT TE EN N   m mu ut ta at ti io on n   
c cr ri it te er ri ia a   ( (6 6   f fa am mi il li ie es s, ,   o on nl ly y    t th he e   c cr ri it te er ri ia a, ,   n no o   P PT TE EN N       d de et te ec ct te ed d   ( (8 8   f fa am mi il li ie es s) )
d de em mo on ns st tr ra at te ed d   m mu ut ta at ti io on n    m mu ut ta at ti io on n   d de et te ec ct te ed d   
c ca ar rr ri ie er rs s   i in nc cl lu ud de ed d) ) ( (2 2   f fa am mi il li ie es s) )
N Nu um mb be er r    M Me ed di ia an n/ /M Me ea an n   a ag ge e N Nu um mb be er r    M Me ed di ia an n/ /M Me ea an n   a ag ge e N Nu um mb be er r    M Me ed di ia an n/ /M Me ea an n   a ag ge e
o of f   p pa at ti ie en nt ts s ( (r ra an ng ge e) )   y ye ea ar rs s o of f   p pa at ti ie en nt ts s ( (r ra an ng ge e) )   y ye ea ar rs s o of f   p pa at ti ie en nt ts s ( (r ra an ng ge e) )   y ye ea ar rs s
B Be en ni ig gn n   n ne eo op pl la as sm ms s
Goitre and/or adenoma 12 29/27.25 (14-38) 1** 34
Polyps of GI tract 10 38/36.5 (22-49)
Haemangioma 8 26.5/28.1  (0.75-54)
Mucocutaneous lesions 9 36/36.6 (22-52) 1 59
Endometrial polyps/simple hyperplasia 7 43/42.4 (29-52)
Benign tumours of the breast 7 33/33.4 (21-50) 1** 25
Lipoma 3 36/27.3 (10-36)
C Ca an nc ce er rs s
Breast  5*  35/35.4 (24-45) 4 42.5/46.5 (25-76) 12 50.5/52 (40-65)
Thyroid  3 13/23 (11-45) 5 50/49.2 (24-84) 11 45/46.4 (22-83)
Brain 3† 42/39  (24-51)
Endometrial 2 39/39  (31-47) 1 67 
Kidney 1 52 1 27
Testicular 1 62
Mediastinal 1 54
Ovarian  2 51.5/51.5 (49-54)
Colon  2 57/57 (49-65)
Prostate  1 58 
Histiocytoma 14 5
Malignant melanoma 2 57.5/57.7 (56-59)
Cervical  13 4
Adrenal 15 6
* two patients had bilateral disease, scored for age at first cancer; † two patients had a gangliocytoma (Lhermitte-Duclos disease), one had a tumour of the pineal 
gland; ** same patient.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2006; 4(4) 184
search for Cowden syndrome without cancer. We
described that in familial cancer all mutation carrying
families had additional Cowden syndrome stigmata. We
have not examined whether or not Cowden syndrome-
like families without cancer may have PTEN mutations.
We have previously reported on frequent cancer
syndromes in Norway; we have a large number of cancer
kindreds in our computerized database, and we found
no additional families when searching for Cowden
syndrome associated cancers. We consider the low
prevalence and the expressions found representative for
Cowden families with cancer.
All families (100%, 95% CI 37-100%) which
fulfilled the Cowden syndrome criteria carried PTEN
mutations, which is in keeping with the previously
reported estimate of 85-90%.[14] Our observed
number of mutation carriers gives an observed
prevalence of 1 per 242,063, which is within Nelen’s
estimate of between 1 per 200,000 and 1 per
250,000 [16]. We found only six families with
mutations, which were considered too few for
meaningful considerations with respect to where in the
gene the mutations were located. 
Twelve (63.2%) patients had benign thyroid
manifestations, which is a little less than three quarters
reported by Merg [7]. The youngest age of onset for
thyroid cancer was 11 years, which indicates that PTEN
mutation carriers contract thyroid cancer both more
frequently and at a younger age than the general
population. Seven (36.8%) patients had benign breast
lesions, compared to earlier reports of 50-60% [3, 6].
Five out of 19 (26.3%) had breast cancer at 24-45 years,
which is within 20-30% and age range as previously
reported [4]. Two (10.5%) patients had endometrial
cancer compared to earlier reports of 6% [3, 7]. Ten
(52.6%) patients had gastrointestinal polyps, which is
close to earlier reports [7]. None of our mutation carriers
had colon cancer. According to Lynch and de la Chapelle
a firm association between Cowden syndrome and
colorectal cancer has yet to be identified, and according
to Eng colorectal cancers are not components of Cowden
syndrome [26, 27]. One (5.3%) of our mutation carriers
had renal cell carcinoma, supporting the notion that renal
cell carcinoma should be added to the operational
criteria for Cowden syndrome [28]. Thus, our findings
add empirical support to established conclusions which
have been questioned because of low numbers reported. 
Nine of 19 (47%) mutation carriers were members
of one kindred. We consider this a finding corresponding
with low and variable fitness in mutation carriers. If so,
the uneven distribution of mutation carriers in families
was a finding and possibly not a statistical problem
reflecting random variation in low numbers. 
In sum, our results were that Cowden syndrome
families had PTEN mutations, while Cowden-like
families and breast and thyroid cancer kindreds did not.
The number of Cowden syndrome-like families was not
more than what might be expected by chance alone.
All examined mutation carriers had clinical signs, and
cancer started to occur before the age of 16. 
In Cowden syndrome families, genetic testing to
identify individuals at risk of contracting cancer cannot
wait until the kindreds are old enough to give informed
consent. We find it reasonable to offer genetic testing
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F Fi ig g. .   1 1. .   Age at onset of first clinical sign estimated by Kaplan-Meier
algorithm for demonstrated mutation carriers. See Table 2 for details
of clinical signs
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Germline PTEN mutations are rare and highly penetrant
in infancy/early childhood. Mutation carriers may be
offered thyroid screening from childhood, and breast
cancer screening may be considered from adolescence
(with MRI, to avoid radiation exposure by mammography
in puberty). Our material is not large enough to conclude
on which age to start breast cancer screening, but the
youngest patient with breast cancer described
internationally was 14 years old [3]. We feel that we
should try to do our best when it comes to screening,
and therefore we recommend that one may consider
breast cancer screening from adolescence.
Non-mutation carriers and members of Cowden
syndrome-like families may not be at risk for cancer in
early age, and may need no special health care in
infancy or adolescence. Thorough clinical genetic work-
up of families and access to genetic testing will
discriminate between those who need health service
from childhood, and those who do not. 
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